Method and kit for prognosis of OPA1 gene induced diseases, E.G. Kjers optic atrophy
US10501798B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 27, 2015 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Jan 8, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/16
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Providing Nuclear factor (erythroid-derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1 and CAT, in their use in the prognosis of an OPA1 gene- or OPA1 gene product-deficit-induced disease, or related complications, e.g. optic atrophy and optic neuropathy, in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by the disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.